Figure 6.

KLF5 promoted cell growth and metastasis through the NF-κB signalling pathway. B-CPAP/KLF5 cells were treated with the specific NF-κB inhibitor SC75741 (5 µM) and the effect was assessed. (A) B-CPAP/KLF5 cells were treated with SC75741 or DMSO for 48 h. Western blotting of cell lysates from B-CPAP/NC, B-CPAP/KLF5, B-CPAP/KLF5+DMSO and B-CPAP/KLF5+SC75741 cells revealed that the NF-κB inhibitor SC75741 decreased the nuclear NF-κB p65 level of B-CPAP/KLF5 cells; and p84 was used as a nuclear marker. (B) Quantified western blotting results. NF-κB inhibitor SC75741 suppressed the (C) proliferation, (D) anchorage-independent growth and (E) migration/invasion ability of B-CPAP/KLF5 cells. NF-κB, nuclear factor-κB; NC, negative control; KLF5, Kruppel-like factor 5; DMSO, dimethyl sulfoxide.